Form 4: Rigel Pharmaceuticals Executive Reports Stock Option Grants After Performance Metrics Met
SEC Form 4 Filing
David A. Santos, EVP and Chief Commercial Officer of Rigel Pharmaceuticals, reports the acquisition of stock options after performance-based conditions were satisfied.
Summary
- David A. Santos, EVP and Chief Commercial Officer of Rigel Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- The report concerns stock options granted to Santos on January 27, 2021, and January 23, 2024, which became reportable on March 17, 2025, after performance metrics were met.
- The options relate to 6,875 and 7,850 shares of Rigel's common stock, respectively, with exercise prices of $35.40 and $12.70.
- These prices and share numbers are adjusted for a one-for-ten reverse stock split effective June 27, 2024.
- The options are now directly owned by Santos.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The satisfaction of performance metrics is a positive sign, but the document primarily reflects routine regulatory filings related to executive compensation.
Positives
- The satisfaction of performance metrics suggests positive progress within Rigel Pharmaceuticals.
- Executive ownership aligns management interests with shareholder value.
Industry Context
Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with the company's performance.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry, often tied to performance metrics.
- Companies like Amgen, Gilead, and Biogen also utilize stock options as part of their executive compensation strategy.
- The vesting schedules and performance metrics associated with these options vary across companies and are often benchmarked against industry peers.
Stakeholder Impact
- The stock option grants could potentially incentivize the executive to drive company performance, benefiting shareholders.
- Employees may view the satisfaction of performance metrics as a positive sign for the company's future.
Key Dates
| Date | Description |
|---|---|
| January 27, 2021 | Date of grant for stock option of 6,875 shares. |
| January 23, 2024 | Date of grant for stock option of 7,850 shares. |
| June 27, 2024 | Effective date of one-for-ten reverse stock split. |
| March 17, 2025 | Date performance metrics were met, triggering reportability. |
| March 19, 2025 | Date of filing. |
| January 27, 2031 | Expiration date of stock option of 6,875 shares. |
| January 23, 2034 | Expiration date of stock option of 7,850 shares. |
Keywords
Rigel Pharmaceuticals, Stock Options, Form 4, Beneficial Ownership, Executive Compensation, Performance Metrics, RIGL, Santos, Reverse Stock Split
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.